Cash Flow from Financial Activities (Quarterly)

Cash Flow from Financial Activities: The net amount of cash transactions used in funding activities.

Atrium Therapeutics, Inc. (RNA) had Cash Flow from Financial Activities of 301.50M for the most recently reported fiscal quarter, ending 2026-03-31.

Quarterly Annual

Figures for fiscal quarter ending 2026-03-31

Income Statement Financials
Revenue	19.64M
Net Income	-16.63M
Cost of Goods Sold	--
Gross Profit	19.64M
Operating Expenses	36.91M
Operating Income	-17.28M
Non-Operating Income/Expense	0.65M
Pre-Tax Income	-16.63M
Normalized Pre-Tax Income	-16.63M
Income after Taxes	-16.63M
Income from Continuous Operations	-16.63M
Consolidated Net Income/Loss	-16.63M
Normalized Income after Taxes	-16.63M
EBIT	-17.28M
EBITDA	-17.13M
Weighted-Average Shares Outstanding (Basic)	17.11M
Weighted-Average Shares Outstanding (Diluted)	17.11M
Earnings per Share (EPS) (Basic)	-0.97
Earnings per Share (EPS) (Diluted)	-0.97
Balance Sheet Financials
Current Assets	285.56M
Property, Plant, and Equipment	4.34M
Long-Term Assets	6.79M
Total Assets	292.36M
Current Liabilities	21.91M
Long-Term Debt	--
Long-Term Liabilities	36.35M
Total Liabilities	58.26M
Common Equity	234.10M
Tangible Shareholders Equity	234.10M
Shareholders Equity	234.10M
Common Shares Outstanding	17.11M
Cash Flow Statement Financials
Cash Flow from Operating Activities	-31.14M
Cash Flow from Investing Activities	-2.10M
Cash Flow from Financial Activities	301.50M
Beginning Cash	--
End Cash	268.26M
Increase/Decrease in Cash	268.26M
Stock-Based Compensation	12.21M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	13.04
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	--
Debt to Equity Ratio	--
Gross Margin	100.00%
Operating Margin	-88.01%
EBIT Margin	-88.01%
EBITDA Margin	--
Pre-Tax Profit Margin	-84.71%
Profit Margin	-84.71%
Free Cash Flow	-33.24M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.07
Inventory Turnover	--
Receiveable Turnover	1.31
Days Sales in Receivables	68.75
Return on Equity	-7.11%
Return on Tangible Equity	-7.11%
Return on Assets	-5.69%
Return on Investments	-7.11%
Book Value Per Share	13.69
Free Cash Flow per Share	-1.94
Operating Cash Flow per Share	-1.82

Data from Zacks Investment Research, Inc.